Cargando…

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain

BACKGROUND: We evaluated the cost-effectiveness of posaconazole compared with standard azole therapy (SAT; fluconazole or itraconazole) for the prevention of invasive fungal infections (IFI) and the reduction of overall mortality in high-risk neutropenic patients with acute myelogenous leukaemia (AM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grau, Santiago, de la Cámara, Rafael, Sabater, Francisco J, Jarque, Isidro, Carreras, Enric, Casado, Miguel A, Sanz, Miguel A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355034/ https://www.ncbi.nlm.nih.gov/pubmed/22471553 http://dx.doi.org/10.1186/1471-2334-12-83

Ejemplares similares

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
por: Cámara, Rafael, et al.
Publicado: (2017)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Drug susceptibility in emerging fungal infections: tests with fluconazole, itraconazole, and amphotericin B
por: Fay, Vanessa da Silva, et al.
Publicado: (2018)

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients
por: Liu, Li, et al.
Publicado: (2023)

Exposure of Cryptococcus neoformans to Seven Commonly Used Agricultural Azole Fungicides Induces Resistance to Fluconazole as Well as Cross-Resistance to Voriconazole, Posaconazole, Itraconazole and Isavuconazole
por: Drakulovski, Pascal, et al.
Publicado: (2023)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

Itraconazole IV solution in the treatment of candidemia in non-neutropenic patients
por: Tuil, O, et al.
Publicado: (2003)

The Effect of Posaconazole, Itraconazole and Voriconazole in the Culture Medium on Aspergillus fumigatus Triazole Resistance
por: Mroczyńska, Martyna, et al.
Publicado: (2020)

Tacrolimus Increases the Effectiveness of Itraconazole and Fluconazole against Sporothrix spp.
por: Borba-Santos, Luana P., et al.
Publicado: (2017)

Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats
por: Khoza, Star, et al.
Publicado: (2017)

Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
por: Wang, Li, et al.
Publicado: (2022)

Mitochondrial Respiratory Pathways Inhibition in Rhizopus oryzae Potentiates Activity of Posaconazole and Itraconazole via Apoptosis
por: Shirazi, Fazal, et al.
Publicado: (2013)

Effects of Cytochrome P450 Inhibitors on Itraconazole and Fluconazole Induced Cytotoxicity in Hepatocytes
por: Somchit, Nhareet, et al.
Publicado: (2009)

Itraconazole Improves Vulvodynia in Fungus Culture-Negative Patients Post Fluconazole Failure
por: Rothenberger, Rodger, et al.
Publicado: (2021)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

Voriconazole in the management of nosocomial invasive fungal infections
por: Pemán, Javier, et al.
Publicado: (2006)

UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats
por: Li, Shuang-long, et al.
Publicado: (2020)

Evaluation of fluconazole, itraconazole, and voriconazole activity on Candida albicans: A case control study
por: Partha, Agung Dewi Sekar Langit, et al.
Publicado: (2022)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis
por: Gonzalez, Javier M., et al.
Publicado: (2015)

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
por: Jansen, Jeroen P., et al.
Publicado: (2010)

Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
por: Tachibana, Masaya, et al.
Publicado: (2023)

Intravenous Itraconazole vs. Amphotericin B Deoxycholate for Empirical Antifungal Therapy in Patients with Persistent Neutropenic Fever
por: Park, Sun Hee, et al.
Publicado: (2006)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients
por: Vallejo, Carlos, et al.
Publicado: (2023)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia
por: Gheith, Soukeina, et al.
Publicado: (2014)

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
por: Allegra, Sarah, et al.
Publicado: (2017)

Long-term management of chronic immune thrombocytopenic purpura in adults
por: Palau, Javier, et al.
Publicado: (2010)

Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination
por: Rojas, Rafael, et al.
Publicado: (2012)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
por: Sanchez-de la Rosa, Rainel, et al.
Publicado: (2013)

Healthcare value of implementing hepatitis C screening in the adult general population in Spain
por: Buti, María, et al.
Publicado: (2018)

Fluconazole prophylaxis of systemic candida infection in non-neutropenic critically ill patients: a prospective randomized study
por: Parizkova, R, et al.
Publicado: (1999)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1r4t3fisbr7427rnh1ihamon6c